Objective-Heme oxygenase-1 (HO-1), the rate-limiting enzyme of heme degradation, has recently been considered to have protective roles against various pathophysiological conditions. Since we demonstrated that HO-1 overexpression inhibits atherosclerotic formation in animal models, we examined the effect of HO modulation on proinflammatory cytokine production, endothelial NO synthase (eNOS) expression, and endothelium-dependent vascular relaxation responses. Methods and Results-After HO-1 induction by heme arginate (HA), vascular endothelial cell cultures were exposed to oxidized low-density lipoprotein (oxLDL) or tumor necrosis factor-␣ (TNF-␣). HA pretreatment significantly attenuated the production of vascular cell adhesion molecule-1, monocyte chemotactic protein-1, and macrophage colonystimulating factor, suggesting that HO-1 induction attenuates proinflammatory responses. In addition, HO-1 overexpression also alleviated endothelial dysfunction as judged by restoration of attenuated eNOS expression after exposure to oxLDL and TNF-␣. Importantly, impaired endothelium-dependent vascular relaxation responses in thoracic aortic rings from high-fat-fed LDL receptor knockout mice were also improved. These effects were observed by treatment with bilirubin not by carbon monoxide. Key Words: heme oxygenase Ⅲ oxidized LDL Ⅲ endothelial nitric oxide synthase Ⅲ bilirubin Ⅲ carbon monoxide V ascular endothelial cell activation by oxidized LDL (oxLDL) and cytokines such as tumor necrosis factor-␣ (TNF-␣) is considered to play an essential role in the development of atherosclerotic lesions. 1 Activated endothelial cells produce adhesion molecules, chemokines, and growth factors such as vascular cell adhesion molecule-1 (VCAM-1), monocyte chemotactic protein-1 (MCP-1), and macrophage colony-stimulating factor (MCSF). [2][3][4] Numerous studies have shown that these molecules promote multiple steps in the formation of atherosclerotic lesion. 1,3,4 Endothelial dysfunction, which is associated with decreased bioavailability of NO from endothelial NO synthase (eNOS), is also considered to play an important role in atherogenesis. 1,5 NO formed by eNOS has been shown to contribute to vascular smooth muscle cell relaxation and inhibition of platelet aggregation. 1 Heme oxygenase (HO) catalyzes the rate-limiting step of heme degradation in mammals. 6 The products of the reaction are biliverdin, carbon monoxide (CO), and free iron. It has been suggested that biliverdin and CO have cytoprotective effects against various cellular stresses. [7][8][9] We demonstrated that the inducible form of HO (HO-1) is induced in cultured vascular endothelial cells, smooth muscle cells, and macrophages by oxidized low-density lipoprotein (oxLDL), and that high expression of HO-1 results in attenuation of monocyte chemotaxis by oxLDL. 9 In fact, HO-1 is expressed in atherosclerotic lesions. 10,11 We also demonstrated that overexpression of HO-1 inhibits the formation of atherosclerotic lesions by inhibiting lipid peroxidation and by affecting NO meta...

Aim: A growing body of evidence has shown that increased formation of oxidized molecules and reactive oxygen species within the vasculature (i.e., the extracellular space) plays a crucial role in the initiation and progression of atherosclerosis and in the formation of unstable plaques. Peroxiredoxin 4 (PRDX4) is the only known secretory member of the antioxidant PRDX family. However, the relationship between PRDX4 and susceptibility to atherosclerosis has remained unclear. Results: To define the role of PRDX4 in hyperlipidemia-induced atherosclerosis, we generated hPRDX4 transgenic (Tg) and apolipoprotein E (apoE) knockout mice (hPRDX4 +/+ /apoE -/ -). After feeding the mice a high-cholesterol diet, they showed fewer atheromatous plaques, less T-lymphocyte infiltration, lower levels of oxidative stress markers, less necrosis, a larger number of smooth muscle cells, and a larger amount of collagen, resulting in thickened fibrous cap formation and possible stable plaque phenotype as compared with apoE -/ -mice. We also detected greater suppression of apoptosis and decreased Bax expression in hPRDX4 +/+ /apoE -/ -mice than in apoE -/ -mice. Bone marrow transplantation from hPRDX4 +/+ donors to apoE -/ -mice confirmed the antiatherogenic aspects of PRDX4, revealing significantly suppressed atherosclerotic progression. Innovation: In this study, we demonstrated for the first time that PRDX4 suppressed the development of atherosclerosis in apoE -/ -mice fed a high-cholesterol diet. Conclusion: These data indicate that PRDX4 is an antiatherogenic factor and, by suppressing oxidative damage and apoptosis, that it may protect against the formation of vulnerable (unstable) plaques. Antioxid. Redox Signal. 17, 1362-1375.

Aims: Consumption of a high-fructose diet (HFrD) can induce the development of a metabolic syndrome, manifesting as nonalcoholic steatohepatitis (NASH) and/or type 2 diabetes mellitus (T2DM), via a process in which oxidative stress plays a critical role. Peroxiredoxin 4 (PRDX4) is a unique and only known secretory member of the PRDX antioxidant family. However, its putative roles in the development of NASH and/or T2DM have not been investigated. Results: To elucidate the functions of PRDX4 in a metabolic syndrome, we established a nongenetic mouse model of T2DM by feeding mice a HFrD after injecting a relatively low dose of streptozotocin. Compared with wild-type (WT), human PRDX4 transgenic (Tg) mice exhibited significant improvements in insulin resistance, characterized by a lower glucose and insulin concentration and faster responses in glucose tolerance tests. The liver of Tg also showed less severe vesicular steatosis, inflammation, and fibrosis, along with lower lipid concentrations, lower levels of oxidative stress markers, more decreased expression of hepatic aminotransferase, and more reduced stellate cell activation than those in the WT liver, reminiscent of human early NASH. Hepatocyte apoptosis was also significantly repressed in Tg mice. By contrast, serum adiponectin levels and hepatic adiponectin receptor expression were significantly lower in WT mice, consistent with greater insulin resistance in the peripheral liver tissue compared with Tg mice. Innovation and Conclusion: Our data for the first time show that PRDX4 may protect against NASH, T2DM, and the metabolic syndrome by ameliorating oxidative stress-induced injury.

No abstract

Abstract-Pulmonary arterial hypertension (PAH) is an intractable disease of the small pulmonary artery that involves multiple inflammatory factors. We hypothesized that a redox-sensitive transcription factor, nuclear factor B (NF-B), which regulates important inflammatory cytokines, plays a pivotal role in PAH. We investigated the activity of NF-B in explanted lungs from patients with PAH and in a rat model of PAH. We also examined a nanotechnology-based therapeutic intervention in the rat model. Immunohistochemistry results indicated that the activity of NF-B increased in small pulmonary arterial lesions and alveolar macrophages in lungs from patients with PAH compared with lungs from control patients. In a rat model of monocrotaline-induced PAH, single intratracheal instillation of polymeric nanoparticles (NPs) resulted in delivery of NPs into lungs for Յ14 days postinstillation. The NP-mediated NF-B decoy delivery into lungs prevented monocrotaline-induced NF-B activation. Blockade of NF-B by NP-mediated delivery of the NF-B decoy attenuated inflammation and proliferation and, thus, attenuated the development of PAH and pulmonary arterial remodeling induced by monocrotaline. Treatment with the NF-B decoy NP 3 weeks after monocrotaline injection improved the survival rate as compared with vehicle administration. In conclusion, these data suggest that NF-B plays a primary role in the pathogenesis of PAH and, thus, represent a new target for therapeutic intervention in PAH. This nanotechnology platform may be developed as a novel molecular approach for treatment of PAH in the future.